Delving into the Latest Updates on MRG006A with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

MRG006A

Target

GPC3

Mechanism

GPC3 inhibitors(Glypican-3 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Advanced Hepatocellular CarcinomaAdvanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Lepu Biopharma Co., Ltd.

Active Organization

Lepu Biopharma Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价MRG006A治疗晚期实体瘤患者的安全性和耐受性；确定MRG006A的最大耐受剂量（MTD）和II期推荐剂量（RP2D）。次要目的：描述MRG006A的药代动力学及免疫原性特征；研究者评估的客观缓解率（ORR）、疾病控制率（DCR）、缓解持续时间（DoR）和无进展生存期（PFS）；评估MRG006A对晚期实体瘤患者QT间期延长的影响。

[Translation]

Primary objectives: To evaluate the safety and tolerability of MRG006A in the treatment of patients with advanced solid tumors; to determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of MRG006A. Secondary objectives: To describe the pharmacokinetic and immunogenic characteristics of MRG006A; investigator-assessed objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS); to evaluate the effect of MRG006A on QT interval prolongation in patients with advanced solid tumors.

Start Date24 Jul 2024

Sponsor / Collaborator

Lepu Biopharma Co., Ltd.

100 Clinical Results associated with MRG006A

Login to view more data

100 Translational Medicine associated with MRG006A

Login to view more data

100 Patents (Medical) associated with MRG006A

Login to view more data

100 Deals associated with MRG006A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	Phase 2	CN	Lepu Biopharma Co., Ltd.	24 Jul 2024
Advanced Malignant Solid Neoplasm	Phase 2	CN	Lepu Biopharma Co., Ltd.	24 Jul 2024